art&scienceoncology G ENE THERAPY is the transfer of selected genes into a host with the hope of ameliorating or curing a disease state. It offers a new treatment paradigm for curing disease. Initially gene therapy was envisioned for the treatment of genetic disorders, but presently in the UK gene therapy research covers a wide range of diseases, including cancer, peripheral vascular disease, arthritis, neurodegenerative disorders and severe combined immunodeficiency syndrome. About 65 per cent of approved gene therapy protocols are for cancer and its treatment in phase I/II trials (Rieger 2001 ).
Gene transfer is the process of insertion of one or more genes into the cell. Genes are transferred to cells via vectors. A vector can be physical as in direct naked DNA injection, chemical such as liposomal encapsulation or viral (Morgan and Anderson 1993) . Viruses are used as vectors because of their innate ability to insert genetic material into the cytoplasm or the genome of a host cell, that is, they infect. The viral vectors that are used for gene therapy trials are adenoviruses. Adenoviruses Adenoviruses were discovered in 1953 as scientists attempted to identify the causative agents of the common cold. In general the viruses currently used in gene therapy are replication deficient, that is, specific regions of the viral DNA essential for replication are deleted.
At University Hospital Birmingham NHS Trust (UHBT) three virus-directed enzyme prodrug therapy (VDEPT) trials are ongoing for liver, head and neck and prostate cancer treatment. In VDEPT the gene delivered to the cancer cells encodes an enzyme that is able to convert a relatively non-toxic prodrug into a highly cytotoxic compound. The ultimate aim of this therapy is to kill the cancer cells while keeping the systemic concentration of toxic compound at a minimal level (Figure 1 ).
All the UHBT clinical trials use direct intratumoural injection of a replication deficient adenovirus (CTL 102), encoding the bacterial enzyme nitroreductase (ML Laboratories 2000a and b). The prodrug CB 1954 is a weak alkylating agent, but when activated by nitroreductase becomes a highly potent bifunctional DNA alkylating agent, that is, a highly cytotoxic compound. CB 1954 is not cell cycle specific once activated unlike most conventional chemotherapy. This approach is augmented by the so called 'bystander effect' in which neighbouring untransduced tumour cells are killed during the prodrug therapy. Study design The UHBT trials are divided into two 'arms': operable and inoperable (Figure 2 ). An 'operable' patient is one whose tumour is scheduled for surgery. These patients are dosed with adenovirus CTL 102. Cohorts of three patients are given an escalating virus dose. Once evidence of nitroreductase expression is seen at a particular dose of CTL 102, patients with inoperable disease will be treated. These patients will receive adenovirus CTL 102, followed two days later by a fixed systemic dose of CB 1954.
The primary objective of the trials is to assess the safety and tolerability of direct intratumoural administration of an adenovirus. Secondary objectives are to show gene expression of nitroreductase in resected specimens and to observe for evidence of prodrug activation after CB 1954 has been administered to patients who have not responded to conventional treatment. Patient recruitment Recruitment to the trials begins when patients attend the relevant clinics. Discussion between nurses and consultants identifies suitable patients. Patients must meet strict inclusion and exclusion criteria set out in the clinical trial protocol: for example they must be over 18 and able to give consent; their condition must be operable and liver, bone marrow and kidney function clinically acceptable. If suitable and interested, patients are given more in-depth explanations about the trial by gene therapy nurses. Information sheets are provided telling 
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patients what to expect when they participate in the trial. Patient screening Baseline patient screening is performed before gene therapy starts. A clinical oncologist performs a medical examination, obtains a full history and written consent for entry into the trial. The target lesion is routinely screened and measured using ultrasound (for liver tumours). A number of blood investigations are made and the patient has an electrocardiogram and chest X-ray. To date the infectious spread of viruses has not been observed and the risk to staff appears to be minimal (Tursz et al 1996) . It is currently not clear whether safety precautions, such as wearing masks, gloves and gowns should be taken. No known risks have been identified, but general consultation between nursing, medical, biological safety officers and hospital health and safety officers favours universal precautions, such as plastic aprons, gloves and standard hand washing procedures, which are known to be effective in preventing the transmission of pathogens such as hepatitis virus or human immunodeficiency virus. Once it can be shown that transmission of the adenovirus remains only a theoretical risk, the strict isolation procedures can be relaxed. The pathway described is for operable patients without prodrug administration. On the morning of the adenovirus injection the patient is admitted to an isolation room with ensuite facilities. Personal belongings are discouraged to minimise infection risk. The virus is prepared in a designated pharmacy clean room, by a pharmacist and technician. The patient receives a local anaesthetic, a research nurse and doctor check the virus, and it is then injected directly into the tumour. There is a theoretical risk of virus leakage resulting in a degree of systemic exposure (virus shedding). However, this represents a small but acceptable level of risk as the immune system of the majority of cancer patients will already have encountered a 'wild type' adenovirus. Post-injection After injection of the virus into the tumour, the patient is required to rest in bed for at least two hours. The research nurses provide a vital role in monitoring the patient and assessing patient tolerance to any side effects of the therapy. Patients might experience flu-like symptoms, tenderness and slight bleeding at the needle injection site. Routine observations are all taken at specified intervals during the day. A risk assessment carried out within the trust states that anyone having direct patient contact must wear disposable protective clothing that must be discarded as clinical waste before leaving the isolation room. On day one blood samples are taken for full blood count, erythrocyte sedimentation rate and clotting. An additional blood sample, stool and urine samples and a throat swab are taken to screen for the presence of the adenovirus. Blood samples have to be adequately packaged and labelled to inform handlers that they might contain genetically modified organisms. The isolation period will remain until there is proof that there is no virus in the urine, saliva, blood or stool; this is a regulatory requirement. At the moment the patient remains in isolation for 24 hours but this is likely to increase with increases in dose escalation. If the results are negative for virus shedding (no virus in the samples taken) a doctor will examine the patient and sign a release form. The patient is then discharged from the isolation room. On day three after virus injection the patient is transferred for his or her scheduled surgery. After surgery resected tumour samples are transported to histopathology for investigation.
The gene therapy advisory committee provide guidance on monitoring gene therapy patients directly after virus administration and for a year during their participation in the trial. As a result of the committee's stipulations, each patient has an intense follow-up schedule for 12 months (Table 1) .
It is the role of gene therapy research nurses to educate members of the nursing team and the wider multidisciplinary team directly or indirectly involved in patient care about gene therapy. Gene therapy nurses have an important role in the multidisciplinary team, reinforcing explanations and information about gene therapy, the treatment, associated side effects, long-term monitoring and patient care plans. It is vital that nurses educate and collaborate with other healthcare professionals because they are instrumental in co-ordinating the patient's overall care. Box 2 details nurse involvement in the trial.
The primary objective of the trial is to determine the safety and tolerability of intratumoural delivery of adenovirus CTL 102 and the secondary objective is to assess the effectiveness of prodrug activation after CB 1954 has been administered. Once a virus dose that expresses a significant level of nitroreductase enzyme is reached, recruitment will expand to incorporate patients with inoperable cancer. A research programme like this might become another option for patients who have not responded to conventional treatments. Gene therapy is an innovative and exciting concept in the field of clinical research, although it will take time and large numbers of patients to demonstrate efficacy
